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Abstract—The abuse of codeine containing combination 
analgesics leads to significant non-opioid toxicities. Cold water 
extraction (CWE) reduces these side effects but can also provide 
access to highly restricted codeine phosphate. This study aims to 
assess the effectiveness of CWE for a range of drug combinations 
available on the Australian market as ’pharmacist-only’ 
medicines. Six products containing codeine phosphate in 
combination with paracetamol, ibuprofen or aspirin as well as an 
excipient free mixture of codeine phosphate and ibuprofen 
lysinate were treated by CWE and the resulting drug content in 
the filtrate analysed by HPLC. The effect of an additional 
acidification step was also assessed for combinations containing 
aspirin and ibuprofen lysinate. It was found that CWE is able to 
remove almost all ibuprofen (up to 97%), but significant amounts 
of paracetamol (between 70% and 80% depending on the 
formulation) and aspirin (nearly 60%) remain in the filtrate. An 
additional acidification step can reduce the residual amount of 
dissolved aspirin to about 42%. The substitution of ibuprofen 
with ibuprofen lysinate allows the removal of the NSAID from 
the filtrate (via CWE followed by acidification) but lysinate as a 
water soluble impurity remains.  
Keywords-Cold water extraction (CWE), HPLC, codeine 
phosphate, codeine containing combination analgesics, ibuprofen 
lysinate  
I. INTRODUCTION
Globally and also on the Australian market, codeine phosphate 
containing analgesics are popular, potent therapeutics. They are 
promoted to relieve mild to moderate pain and are also used in cold 
and flu formulations to alleviate body aches. In these analgesic 
formulations codeine phosphate is usually combined with a non-
opioid agent like ibuprofen, paracetamol or aspirin. Since codeine is 
partially metabolized to morphine and hence causes neurological 
effects, abuse of these products by heroin and morphine addicts is 
common. According to the 2013 Australian National Drug Strategy 
Household Survey [1], for example, the percentage of Australians 
aged 14 years or older who use pain killers for non-medical purposes 
has nearly doubled from 1.7 to 3.3% over the past 20 years. In 2009 
the number of deaths specifically related to codeine use also more 
than doubled over the previous decade to 8.7 per million. In more 
than half of the investigated cases paracetamol, ibuprofen or 
doxylamine were also detected, indicative of the dangers associated 
with the accidental or intentional abuse of codeine containing 
combination analgesics [2]. These Australian trends are also 
replicated in many other countries. 
The maximum daily dose of codeine considered safe is 240 mg. 
Overdosing can lead to physical and psychological dependence and 
respiratory depression [3]. However, the focus of this paper is not 
primarily the potential harm associated with codeine abuse itself. In 
light of a concerning body of evidence documenting the addiction 
potential and abuse of codeine containing combination analgesics 
(CCCAs), this study directs attention to the toxicity of non-opioid 
pain killers associated with an intake of large doses of CCCAs. Well 
documented non-opioid toxicities include, for example, the 
hepatotoxic effect of the paracetamol metabolite N-acetyl-p-
benzoquinone imine that causes severe liver damage in case of 
paracetamol overdose [4], whereas ibuprofen and aspirin can lead to 
NSAID toxicity including gastrointestinal ulceration and bleeding, 
renal failure, anaemia and also hypokalaemia [5-7]. Acknowledging 
these problems, in 2010 the Australian Government’s National Drugs 
and Poisons Schedule Committee changed the scheduling of 
combination analgesics containing up to 5 days treatment and up to 
12 mg codeine (equivalent to 15.4 mg codeine phosphate) per divided 
dosage unit (e.g. tablet, capsule) from ‘pharmacy medicines’ (S2) to 
‘pharmacist-only medicines’ (S3). Undivided preparations such as 
mixtures have been reclassified in a similar manner and combinations 
with a codeine content exceeding these limits have since been 
classified as ‘prescription only medicines’ (S4) [8]. At present, 
Australia’s Therapeutic Goods Administration considers to move 
even a step further with its Advisory Committee on Medicines 
Scheduling seeking comments on a proposed reclassification of all 
codeine formulations from S3 to S4 to take effect in July 2017 [9]. 
Most chronic users are aware of the dangers of analgesic abuse. 
To avoid non-opioid toxicities a simple chemical manipulation of 
CCCAs is currently promoted on many websites and forums popular 
amongst opioid addicts. Known as cold water extraction (CWE) 
warm water is added to crushed tablets, the resulting suspension is 
cooled and filtered to remove the unwanted non-narcotic analgesics 
(the filtrate contains the water soluble codeine phosphate). While 
only sparse scientific data exists on the effectiveness of this method, 
chemically the approach is very plausible, as the solubility of codeine 
phosphate in water is about 250 mg per ml [10], whereas the 
solubility of paracetamol is only approximately 14 mg per ml, that of 
aspirin 4.6 mg per ml and of ibuprofen only 0.02 mg per ml [11].  
However, while CWE might be a strategy to avoid excessive 
non-opioid toxicities associated with the abuse of CCCAs, if 
successful, it also opens up a convenient avenue to obtain large 
quantities of codeine phosphate, a highly controlled and restricted 
Schedule 8 drug in Australia. Codeine obtained in this way could for 
example be used as starting material for the manufacture of home 
bake heroin [12-13]. 
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TABLE I.  INVESTIGATED COMBINATION ANALGESICS 
*Also contains doxylamine succinate 5 mg 
 
CWE can thus be seen as a double edged sword – to avoid associated 
NSAID toxicities on the one hand its success is desirable for those 
intending to abuse CCCAs in large quantities; intake of 40 tablets a 
day is common, with some abusers taking up to 100 tablets daily [6]. 
On the other hand, however, it opens up simple and convenient 
access to a highly restricted Schedule 8 drug. 
In this light the aim of this study was to investigate the effectiveness 
of CWE for six popular CCCAs available as pharmacist-only 
medication (S3) in Australia (Tab. 1). Taking into account the 
solubility and chemical characteristics of the non-opioid analgesic, 
for the combination containing aspirin the effectiveness of an 
additional acidification step was also assessed. In all cases the 
success of CWE was judged via HPLC analysis by the purity and 
yield of the obtained codeine phosphate solution. Beside the 
commercially available analgesic products a mixture of codeine 
phosphate with ibuprofen lysinate was also investigated to see if a 
change in formulation might impede on the accessibility of pure 
codeine phosphate via CWE (including acidification of the obtained 
filtrate) without compromising its effectiveness in minimising non-
opioid toxicities in those abusing these combination analgesics in 
large quantities.  
 
II. MATERIALS AND METHODS 
A. Materials 
Samples analysed in this study are listed in Table 1. Products A-F are 
commercially available, Product G is an excipient free mixture of 
codeine phosphate and ibuprofen lysinate, which was synthesised 
following a method reported by Kumudhavalli et al. [14]. Pure 
codeine phosphate, aspirin and ibuprofen were sourced from PCCA 
Australia Pty Ltd. (Matraville, NSW, Australia) and paracetamol from 
Sigma-Aldrich Australia (Castle Hill, NSW, Australia). DL-Lysine 
98% monohydrate was purchased from Alfa Aesar Heysham, UK, 
hydrochloric acid (32%) was obtained from ACE Chemicals 
(Camden Park, SA, Australia), monobasic potassium dihydrogen 
phosphate (KH2PO4), acetonitrile (ACN, HPLC grade) and formic 
acid were sourced from Ajax FineChem (Tarren Point, NSW, 
Australia) and ninhydrin (analytical grade) from Chem Supply 
(Gillman, SA, Australia). Deionised water was obtained by reverse 
osmosis using a Boss 031-4P filtration system (PSI Water Filters, 
Tasmania, Australia).  
B. HPLC and UV-Vis Assays of Codeine Phosphate, 
Paracetamol, Aspirin, Ibuprofen and Ibuprofen Lysinate 
A Hewlett Packard Series 1100 Pump and Autosampler with a diode 
array detector (λ=254 nm) (Agilent Technology, Australia) fitted with 
a Gemini NX-C18 column (150 X 4.6 mm, 5 um particle size) 
obtained from Phenomenex (Lane Cove, NSW, Australia) was used 
for HPLC analyses at a flow rate of 1.0 mL/min.  
In the assay of codeine phosphate, paracetamol and aspirin solvent A 
was ACN and solvent B was a phosphate buffer (0.015M KH2PO4, 
pH 2.5±0.2). A gradient was run with 70% B for the first 9 minutes, 
then linearly converted to 0% B over 6 minutes, and changed back to 
70% B over 2 minutes, with a complete run time of 22 min [15-16]. 
For the HPLC analysis of ibuprofen and ibuprofen lysinate a mixture 
of 60% ACN, 39.9% deionised water and 0.1% formic acid was used 
as mobile phase. The runtime of this assay was 10 min [17]. All 
standards and samples were analysed in triplicates. 
The UV-Vis analysis of lysine was carried out on a Varian Cary 50 
Bio UV-Vis Spectrophotometer at 570 nm after colorimetric reaction 
of the samples with ninhydrin reagent (8% in acetone) in accordance 
with a method developed by Meyer [18]. 
C. Cold Water Extraction 
For Products A-E 24 tablets and for Product F 20 tablets respectively 
were crushed to a powder using a porcelain mortar and pestle. 
Samples of approximately 4g powder were accurately weighed into 
250ml volumetric flasks and made up to volume with deionised water 
heated to 40 °C. The suspension was cooled for 4 hours at 4 °C and 
then filtered through a Whatman 15cm filter paper. The filtrates were 
diluted 1:10 with deionised water and analysed via HPLC. Further, 
samples were prepared by mixing accurately weighed amounts of 
approximately 1.6 g ibuprofen lysinate and 102 mg codeine 
phosphate, a mixture that is equivalent in drug content to 8 tablets of 
Product E. The powder mixture was subjected to CWE as described 
above, also diluted 1:10 with deionised water and analysed via 
HPLC. All recovered drug amounts in the filtrates are expressed as 
mean percentage content (n=3) ± standard deviation. 
D. Additional Acidification Step 
An additional acidification step was carried out with the filtrates 
obtained from Products F and G after CWE. 10 ml of each filtrate 
were acidified either with 1 ml of HCl or 5 ml of commercially 
available lemon juice (to mimic the home environment of abusers). 
The resulting precipitate was removed via gravity filtration, the 
collected acidified filtrates were diluted 1 in 10 with deionised water 
and analysed by HPLC. Recovered drug amounts in the acidified 
filtrates are expressed as mean percentage content (n=3) ± standard 
deviation. 
III. RESULTS 
Table 2 summarises the results obtained from the CWE of the six 
commercially available formulations as well as the mixture of 
codeine phosphate and ibuprofen lysinate. Table 3 summarises the 
effect of the additional acidification step on filtrates obtained from 
CWE of samples containing aspirin or ibuprofen lysinate as a non-
opioid analgesic component. 
IV. DISCUSSION 
As can be seen from the data presented in Table 2 CWE provides a 
simple avenue to partly remove non-opioids from CCCAs. However, 
the degree of success, expressed as the yield of codeine phosphate in 
the obtained filtrate as well as of the residual non-opioid analgesic, 
varies significantly depending on the type of NSAID in the analgesic 
combination. In line with their respective aqueous solubilities CWE 
is able to remove almost all ibuprofen (up to 97%), but significant 
residual amounts of paracetamol (between approximately 70% and 
80% depending on the formulation) and aspirin (nearly 60%) remain 
Sample 
label 
 
 
Dosage 
Form 
 
 
Type of  
NSAID 
NSAID 
per dose  
(in mg) 
 
Codeine 
phosphate  
per dose 
(in mg) 
A Tablet Paracetamol 500 6.0 
B* Tablet Paracetamol 450 9.75 
C Tablet Paracetamol 500 15.0 
D Tablet Paracetamol 500 8.0 
E Tablet Ibuprofen 200 12.8 
F 
Effervescent 
tablet 
Aspirin 300 
 
8.0 
 
G - 
Ibuprofen  
Lysinate 
200 
 
12.8 
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in the filtrate after CWE is carried out as described in a number of 
internet drug fora. 
TABLE II.  DRUG RECOVERY RATE IN FILTRATE AFTER CWE 
 
TABLE III.  DRUG RECOVERY RATE AFTER CWE AND ACIDIFICATION 
 
It can be speculated that CWE might originally have been devised for 
ibuprofen containing combinations and then, without further 
chemical considerations, been extended to other combinations 
containing different NSAID components. This is of concern as 
abusers might have a false sense of security carrying out CWE with 
combinations other than those containing ibuprofen and be unaware 
of the potential residual non-opioid toxicity of these filtrates. For 
example, based on the findings of this study, taking 10 tablets of 
Product F after CWE still leaves a residual aspirin amount of about 
1.7 g. Similarly, in the case of Products A-D such a dose would result 
in between 3.1 and 4.2 g of paracetamol, which is well above the 
recommended dose of 300–900 mg every 4–6 hours [3]. 
As a relatively strong acid with a pKa of 3.49 [19], aspirin can be 
expected to be mainly ionised in the slightly acidic drug powder 
suspension (approximately pH 5) leading to a large amount of the 
drug dissolved and carried over into the CWE filtrate. For this reason 
an acidification step with HCl, but also with household lemon juice 
(to better reflect the home environment where CWE would normally 
be carried out) was trialled and its impact on the yield and purity of 
the obtained codeine phosphate solution assessed. As can be seen 
from the obtained data (Tab. 3), this simple additional acidification 
step, independent of the nature of the acid used, was successful in 
reducing residual amounts of dissolved aspirin from the original 
CWE filtrate, lowering the percentage residual amount of aspirin 
from about 57% to 42% of the original dose. While, to our 
knowledge, currently not promoted in relevant internet fora, such an 
acidification step should make the abuse of aspirin-codeine phosphate 
combination analgesics safer, although there will still be the danger 
of significant residual NSAID toxicity.  
In terms of potential access to relatively pure codeine phosphate 
the combination with ibuprofen is most concerning. While the opioid 
yield after CWE is with about 80% not as high as with some of the 
other investigated formulations, the filtrate is by far the purest 
showing only very small amounts (approximately 3%) of residual 
NSAID. This concern has prompted the investigation of a potential 
change in drug composition for this particular combination analgesic, 
replacing ibuprofen with ibuprofen lysinate, a highly water soluble 
salt that is currently found in a number of formulations as a fast 
acting analgesic. The rationale for this substitution is two-fold: Due 
to its salt properties ordinary CWE will lead to a highly contaminated 
codeine phosphate solution. For those who intend to abuse this 
combination and thus aim to remove ibuprofen to avoid associated 
NSAID toxicities, a simple acidification step following CWE will be 
sufficient (Tab. 3) since, based on pH and solubility, ibuprofen free 
acid will almost quantitatively precipitate out of solution 
(approximately 2% residual ibuprofen in acidified filtrate) and can 
thus easily be removed by gravity filtration. However, in contrast to 
other ibuprofen-codeine phosphate combinations currently on the 
market, the use of ibuprofen lysinate leaves lysinate as a water 
soluble impurity in the acidified filtrate as was demonstrated by UV 
Vis analysis after colorimetric reaction of the samples with ninhydrin. 
As a naturally occurring basic amino acid lysine is not anticipated to 
cause any health concerns but as a contaminant in the filtrate will 
impact negatively on access to a highly restricted Schedule 8 
substance. While explored only at a conceptual level without 
consideration of formulation issues, using ibuprofen lysinate in 
CCCAs might thus be an interesting approach warranting further 
investigation. As is illustrated in Figure 1, it should still be possible 
for abusers trying to avoid non-opioid toxicities to effectively remove 
the NSAID component via CWE followed by acidification, but due to 
significant contamination of the acidified filtrate with lysinate access 
to large quantities of relatively pure codeine phosphate is impeded. 
 
 
 
Figure 1. Drug recovery from Product G 
 
V. CONCLUSION 
This study contributes to the still sparse scientific data on the 
effectiveness of CWE of CCCAs. It has been shown that depending 
on the NSAID used codeine phosphate of varying purity and yield 
can be obtained from these analgesics that are currently in Australia 
sold as Schedule 3 (pharmacist-only) products. The data set thus 
weighs into the current debate on a possible rescheduling of these 
formulations to a prescription only (S4) status. With codeine 
phosphate and ibuprofen lysinate a new analgesic combination has 
been explored at a conceptual level that might in the future be 
considered as an alternative to the ibuprofen containing combination 
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Product G               Product G            Product G
acidified              acidified
with HCl             with lemon juice
Codeine phosphate Ibuprofen Lysine
Sample 
label 
 
 
Type of  
NSAID 
Codeine  
phosphate  
% recovery 
(mean ± SD, n=3) 
NSAID 
% recovery 
(mean ± SD, n=3) 
A Paracetamol 75.61  ± 8.67 75.53 ± 5.92 
B Paracetamol 93.15  ± 0.93 68.91 ± 1.63 
C Paracetamol 103.53 ±  9.72 83.51 ± 4.00 
D Paracetamol 100.28 ± 4.75 61.18 ± 1.32 
E Ibuprofen 79.94 ± 9.61 2.87±0.22  
F Aspirin 62.43 ± 2.60 56.96 ± 6.24 
G 
Ibuprofen  
lysinate 
100.04 ± 12.43 93.05 ± 13.98 
Type of 
NSAID 
Codeine phosphate  
% recovery 
NSAID 
% recovery 
HCl 
(mean ± SD,  
n=3) 
Lemon  
juice 
(n=1) 
HCl 
(mean ± SD,  
n=3) 
Lemon  
juice 
(n=1) 
Aspirin 
 
89.70 ± 5.49 - 41.75 ± 4.62 - 
Ibuprofen 
lysinate 
102.07 ± 2.72 100.01 2.33 ± 0.20 2.57 
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formulations currently on the market. This combination might still 
allow abusers of these products to avoid NSAID toxicity via CWE 
followed by acidification while at the same time prohibiting easy 
access to relatively large quantities of pure codeine phosphate, which 
in Australia is a highly regulated and restricted drug (S8). The 
findings of this study might therefore also be of interest to 
manufacturers and regulatory authorities. 
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